Berera, Shivali http://orcid.org/0000-0001-9729-3951
Lichtenstein, Gary R.
Article History
Accepted: 10 January 2022
First Online: 25 February 2022
Declarations
:
: Shivali Berera declares that she has no conflict of interest. Gary R. Lichtenstein has served as a consultant for Abbie, American Regent, Bristol Meyers Squibb, Celgene, Eli Lilly (Data Safety Monitoring Board), Endo Pharmaceuticals, Ferring, Gilead, Janssen Orthobiotech, MedEd Consultants, Merck, Morphic Therapeutics, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals, Valeant (Bausch Health) Pharmaceuticals, Shire Pharmaceuticals, Takeda Pharmaceuticals, UCB, Virgo (stock options); CME participant for Allergan, American Gastroenterological Association, American Regent, Chemed, IMEDEX, Ironwood, Merck, Romark, University of Kentucky, Vindico; Author/Editor with honorarium/royalty for Up-To-Date, Springer Science and Business Media, SLACK, Inc., Professional Communications, Inc., Gastroenterology and Hepatology Communications, American College of Gastroenterology; and has obtained funding for Inflammatory Bowel Disease Fellow Education from Janssen Orthobiotech and Pfizer Pharmaceuticals.
: This article does not contain any studies with human or animal subjects performed by any of the authors.